TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cancer specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Type 2 Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate to categorize blood glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Tissue Gli1 Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of leg telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: successful pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Pain with IV Cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in parameters of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static 2PD test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate Intensity Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence (dose count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence (dose time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to daily self-monitoring of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Microvascular Blood Flow (PMBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MMP-9-TIMP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quick Inventory of Depressive Symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Device Wear Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient reported outcome scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain Up to 28 Days After the First Active Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Antibody Titers of the Respective Homologous JE Vaccine Strain After the First Active Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting at Least One Treatment Emergent Adverse Event Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Fragility fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hours post-operatively to mobilise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of assistance required for functional tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to walk 10 metres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time able to stand on operative leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGFR < 60 mL/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: albuminuria/creatinine ratio >=30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: proteinuria/creatine ratio >=150
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum observed concentration of 14C JNJ-38518168 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum observed concentration of 14C JNJ-38518168 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Cladribine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Cladribine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Goal Attainment Scale (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Social Skills Assessment Questionnaire (SSAQ)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of participants experiencing maternal HIV progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of small-for-gestational age infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of stunted infants (height-for-age z-score < -2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During Second Unassisted Use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient and companion acceptability of medical education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decline in Serum PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sentinel nodes detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post prandial partitioning of exogenous lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of SPI-1620
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time with glucose values < 3.9 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of carbohydrate interventions to treat hypoglycemia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: In-hospital Seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetes status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular control: Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of microorganisms on wound bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of influenza immunization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effect of hyperemesis gravidarum on eye health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor and node response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normalized Hemoglobin (Hb AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean drinks per drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female Sexual Function Index (FSFI) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pathologic Complete Response Rate (pCR Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with positive pregnancy test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Monocytic populations involved in bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Seroconverted Subjects Against H5N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against H5N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against H5N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage Change in Total AKN Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Patients Who Experienced Significant Nonhematologic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: nutritional recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative bioavailability of testosterone and dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-Regional Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: COPD exacerbation recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Time Spent in Hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in total blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in red blood cell volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to castration-resistant prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: rPFS6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholecystokinin serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oxytocin serum bioassay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastric Emptying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perception of fullness using visual analog scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: evoked spinal reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Peak VO2 (Oxygen Consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Unanticipated adverse device effects (UADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent mitral valve insufficiency > grade 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Worst Pain in the past 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to mammographic density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate by CT Scan Using RECIST Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with clinical responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients in Whom Tumor Was Resectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to onset of pain (TInitial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum pain tolerance (TEnd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of alcohol use disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient acceptability as measured by CCBT sessions completed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cellular changes after trastuzumab treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of HIV-1 gag DNA vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Performance in maximal barrier precaution (MBP) technique during CVC placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Reporting Improvement on the Clinical Global Impression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Accurate Diagnoses of Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Infant Weight-for-Age Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily Plasma F2-Isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal Dilution Cardiac Index (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: health status after early discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-Free Survival (PFS) at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: change in metabolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of new lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of AK lesions showing complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathology assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endoplasmic reticulum stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly utilization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Enablement Instrument (PEI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of individuals receiving recommended cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of multimodal MRI parameters on brain connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of cognition measured by a battery of neuropsychological tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time in months since start of medication till seizure control is attained
Endpoint domain: Mortality/survival
Primary endpoint: Reference ranges for glucose in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastrointestinal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in distress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in craving self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Estimation of total tumor load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis of high-risk neurofibromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tau Protein Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of on-line questionnaire for diagnosing episodic migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical tolerance to peanut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity according to CTCAE v.5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Healing in Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major pathological response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nerve Growth Factor (NGF) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biomarker levels of leucine rich glioma inactivated 1 associated encephalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarker levels of anti leucine rich glioma inactivated 1 associated encephalitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Concentration of Anifrolumab in Serum After First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 21-gene Type 1 IFN Signature Score (Fold-change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in muscle extension isokinetic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in 4 min speed step
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic Geometric Center at 24 Hours (GC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain Intensity Difference (PID) over 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarettes per Smoking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a calcified apical barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility outcome
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of therapy-related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Level of severity of therapy-related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Number of Missed Working Days Due to Sick Leave in the Past 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Health-Assessment Questionnaire-Disability Index (HAQ-DI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EuroQol-5 Dimensions (EQ-5D) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Abscopal effect rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inventory of Psychosocial Functioning (IPF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Quality of Life - Brief Form (WHOQOL-BF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Illness Intrusiveness Rating Scale (IIRS)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in zinc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Allogenic Blood Transfusion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Units of Packed Red Blood Cells Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of radioactive dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort perception after pumping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Handling experience with breast shields
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensation per breast shield
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IgG half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extravascular lung water change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in viral load (log10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Growth standard calculated z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms associated with infant colic
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in participant knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in participant confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing